Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Primary Cutaneous CD30 positive Lymphoproliferative Disorders—Current Therapeutic Approach with Focus on Brentuximab Vedotin

Version 1 : Received: 9 November 2023 / Approved: 10 November 2023 / Online: 13 November 2023 (08:27:17 CET)

A peer-reviewed article of this Preprint also exists.

Stein, T.; Robak, T.; Biernat, W.; Robak, E. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin. J. Clin. Med. 2024, 13, 823. Stein, T.; Robak, T.; Biernat, W.; Robak, E. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin. J. Clin. Med. 2024, 13, 823.

Abstract

One of the most common subgroups of cutaneous T-cell lymphomas is the that of primary cutaneous CD30 positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders. This review article summarizes the clinical evidence supporting the current treatment options in these diseases. Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target, and describes the anti-CD30 therapies that have emerged to date.

Keywords

Anaplastic large cell lymphoma; Brentuximab vedotin; CD30 positive lymphomas; Diagnosis; Lymphomatoid papulosis; Primary cutaneous T-cell lymphoma; Treatment

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.